問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Surgery

Division of Hematology & Oncology

National Taiwan University Hospital Hsin-Chu Branch

Division of Hematology & Oncology

National Taiwan University Cancer Center

Division of Hematology & Oncology

更新時間：2023-09-19

張端瑩
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

155Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張端瑩

List

262Cases

2023-06-30 - 2029-02-28

Phase III

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy

  • Condition/Disease

    Locally Advanced or Unresectable Metastatic Breast Cancer 、Stage IV Breast Cancer

  • Test Drug

    Trodelvy

Participate Sites
10Sites

Not yet recruiting10Sites

2016-07-01 - 2024-10-31

Phase II

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

  • Condition/Disease

    INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

  • Test Drug

    Tazemetostat (EPZ-6438)

Participate Sites
1Sites

Recruiting1Sites

2023-11-01 - 2026-12-31

Phase III

An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  • Condition/Disease

    Metastatic Breast Cancer

  • Test Drug

    Lasofoxifene

Participate Sites
7Sites

Recruiting7Sites

2020-11-01 - 2026-06-30

Phase III

Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)

  • Condition/Disease

    Advanced/Metastatic Gastroesophageal Adenocarcinoma

  • Test Drug

    吉舒達注射劑R/Keytruda injectionR樂衛瑪膠囊R/ Lenvima capsuleR

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2018-04-19 - 2023-12-31

Phase III

A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)

  • Condition/Disease

    Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Test Drug

    KEYTRUDA

Participate Sites
7Sites

Terminated7Sites

2015-09-01 - 2019-12-31

Phase III

A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Condition/Disease

    Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
4Sites

Terminated4Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-10-01 - 2019-12-31

Phase III

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) – (KEYNOTE 119)

  • Condition/Disease

    Metastatic Triple Negative Breast Cancer (mTNBC)

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
5Sites

Terminated4Sites

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

邱昌芳
China Medical University Hospital-Taipei

未分科

2015-04-01 - 2020-12-31

Phase III

A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine

  • Condition/Disease

    Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
4Sites

Terminated4Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-07-26 - 2020-06-30

Phase III

A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)

  • Condition/Disease

    Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
6Sites

Terminated5Sites

Study ended1Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2015-12-14 - 2020-10-31

Phase III

A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)

  • Condition/Disease

    Colorectal Carcinoma

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
5Sites

Terminated5Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

1 19 20 21 22 23 27
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB